ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Today, we celebrate two decades of experience with imatinib and later-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML).